Benzinga | Oct 27, 2021 08:06AM EDT

Aptevo Therapeutics Presents Clinical Data On Lead Leukemia Drug Candidate APVO436 At Second Virtual Conference On Controversies In Leukemias, Euroleuk2021

Aptevo Therapeutics Inc. ("Aptevo" or "the Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR(tm) and ADAPTIR-FLEX(tm) platform technologies, will participate at the 2nd Virtual Congress on Controversies in Leukemias (EuroLeuk), an international leukemia symposium which is being held October 28-29, 2021, with a Poster Presentation. The poster abstract was selected as one of the best abstracts and included into the Congress program as an oral presentation as well. Euroleuk2021 will provide clinicians and biologists with state-of-the-art recommendations regarding patient care and insights into controversies and new therapeutic perspectives in the field ( https://euroleuk2021.com/).

The Aptevo presentations will focus on the clinical safety, pharmacodynamics, and efficacy signals obtained so far during the ongoing multi-institutional Phase 1B clinical study of Aptevo's lead leukemia drug candidate APVO436 in 46 adult patients with relapsed or refractory acute myelopid leukemia (AML) or myelodysplastic syndrome (MDS). Both the oral slide presentation and the poster presentation will be delivered by the lead author Dr. Fatih Uckun, the leukemia expert and Chief Clinical Advisor of Aptevo. The shared title of the talk and poster is: CD3xCD123 Bispecific Antibody APVO436 for Biotherapy of Relapsed/Refractory AML/MDS. Dr. Uckun's co-authors are Dr. Justin Watts (University of Miami), Dr. Tara L. Lin (University of Kansas), Dr. Alice Mims (The Ohio State University), Dr. Prapti Patel (University of Texas Southwestern Medical Center), Dr. Paul Shami (University of Utah), Dr. Elisabeth Cull (Greenville Health System), Dr. Christopher R. Cogle (University of Florida), Dr. Cynthia Lee (Aptevo Therapeutics), and Dr. Eunice Wang (Roswell Park Comprehensive Cancer Center).

"We are very excited about the APVO436 data, demonstrating that our lead drug is generally well tolerated and showing preliminary signs of efficacy in the treatment of patients with relapsed or refractory AML and MDS who are in urgent need for new therapeutic options," said Marvin White, CEO of Aptevo. "Our work on APVO436 is on-going and we look forward to sharing new outcomes, as they become available."